[Case of tuberculous lymphadenitis of the superior mediastinum].
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to T Kitahara.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
As early as 3--4 hours after infection with SV40 at a high input multiplicity, African green monkey (Cercopithecus aethiops) kidney (AGMK) cells developed cytoplasmic vacuolization. At 10--20 hours after infection, the vacuolization reached its maximal level, then disappeared and SV40 specific cytopathic change followed. This vacuolization developed before the synthesis of the specific T and V antigens. This early cytoplasmic vacuolization (ECV) was prevented by preincubating the virus with specific antiserum, or by heating the virus with MgCl2. The ECV could be induced by UV-irradiated SV40. Addition of metabolic inhibitors had no effect on the induction of the ECV. These results suggest that the capacity to induce the ECV resides in a structural component(s) of SV40 virion and the vacuolization is not associated with the replication of SV40.
A new antibiotic named SS-228 Y, which inhibits growth of Gram-positive bacteria, Ehrlich carcinoma in mice, and dopamine-beta-hydroxylase, was obtained from a species of Chainia isolated from shallow sea mud in Sagami Bay. It was yellowish brown powder having the molecular formula C19H1406. From the physical and chemical properties, SS-228 Y was concluded to b a new antibiotic having structure of peri-hydroxyquinone moiety.
The action of amiclenomycin (AM) in inhibiting growth of microorganisms is specific against mycobacteria in vitro, but the antibiotic does not show a therapeutic effect against tubercle bacilli in vivo. The action of AM is reversed by biotin, desthiobiotin (DTB) and 7,8-diaminopelargonic acid (DAPA), but not by 7-keto-8-aminopelargonic acid (KAPA), pimelic acid and glutaric acid. In the presence of AM, cultures of Mycobacterium smegmatis and Bacillus sphaericus accumulated KAPA, whereas the formation of DTB decreased. Therefore, AM is thought to inhibit KAPA-DAPA transamination in biotin biosynthesis. In M. smegmatic and B. sphaericus the conversions of KAPA to DAPA and of DTB to biotin were rate limiting in biotin synthesis. Accordingly, the synergistic antibiotic activity of AM, inhibiting the former, and actithiazic acid, inhibiting the latter reaction, would be simply explained.
Amiclenomycin (AM) was found to be a strong inhibitor of KAPA-DAPA aminotransferase of Brevibacterium divaricatum. This transamination was suggested to follow Ping Pong Bi Bi mechanism. Inhibition of this transamination by AM is of a noncompetitive type in a Lineweaver-Burk plot of initial velocity, but not in a Dixon plot. The activity of KAPA-DAPA aminotransferase drops abruptly after preincubation with AM, but its activity is restored by dialysis against 10 mM potassium phosphate buffer (pH 7.0). Inhibition by AM is decreased by an increase of KAPA in the reaction mixture, but not by an increase of S-adenosyl-L-methionine (SAM) or pyridoxal-5'-phosphate (PALP). These facts indicate that AM exerts its inhibitory action against KAPA-DAPA aminotransferase by binding to the enzyme, probably to the KAPA-DAPA binding site.
DB-2073 (I), an antibiotic produced by Pseudomonas sp. B-9004, was obtained as a pure crystals state having a formula of C15H24O2 (ME 236). The characterization indicated that I was a resorcinol antibiotic and it was elucidated as 2-n-hexyl-5-n-propylresorcinol.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.